<DOC>
	<DOCNO>NCT02341482</DOCNO>
	<brief_summary>The purpose current study characterize pharmacokinetic ( PK ) profile PF 04958242 co administer strong cytochrome P450 3A4 ( CYP3A4 ) inhibitor .</brief_summary>
	<brief_title>A Study Evaluate Effect Itraconazole Pharmacokinetics PF-04958242 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Healthy male subject female subject non childbearing Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 55 kg ( 121 lb ) . Subjects ANY follow abnormality clinical laboratory test screen , assess study specific laboratory confirm single repeat , deem necessary : Aspartate transaminase ( AST ) /serum glutamic oxaloacetic transminase ( SGOT ) alanine transaminase ( ALT ) /serum glutamic pyruvic transminase ( SGPT ) &gt; =1 x upper limit normal ( ULN ) ; Total bilirubin &gt; =1.5 x ULN ; subject history Gilbert 's syndrome may direct bilirubin measure would eligible study provide direct bilirubin &lt; = ULN . Subjects epilepsy , history epilepsy , condition low seizure threshold , seizures etiology ( include substance drug withdrawal ) , increase risk seizure evidence self report history electroencephalogram ( EEG ) epileptiform activity . Subjects history childhood seizures history head trauma loss consciousness require hospitalization overnight exclude well . Subjects history allergy intolerance azole antifungal drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Itraconazole</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>PF-04958242</keyword>
</DOC>